The presence of these concurrent mutations, particularly KEAP1, has been associated with reduced response rates to KRAS G12C inhibitors in NSCLC [8], while STK11 mutations are associated with decreased immune sensitivity [30]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.